Status:
COMPLETED
Investigating the Effectiveness of Eylea in Patients With Wet Age-related Macular Degeneration
Lead Sponsor:
Bayer
Collaborating Sponsors:
Regeneron Pharmaceuticals
Conditions:
Wet Age-related Macular Degeneration
Eligibility:
All Genders
Brief Summary
The study aims to investigate the effectiveness of Eylea in patients with wet age-related macular degeneration in routine clinical practice in Germany. The study is purely observational, only data fro...
Eligibility Criteria
Inclusion
- Patients with wet wAMD treated with Eylea (in accordance with the local Summary of Product Characteristics, SPC).
- Written informed consent.
Exclusion
- Exclusion criteria as listed in the local SPC.
- Scar, fibrosis, or atrophy involving the center of the fovea in the study eye.
- Any concomitant therapy with another agent to treat wet AMD in the study eye.
Key Trial Info
Start Date :
July 29 2013
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 31 2017
Estimated Enrollment :
988 Patients enrolled
Trial Details
Trial ID
NCT01914380
Start Date
July 29 2013
End Date
March 31 2017
Last Update
March 29 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Multiple Locations, Germany